These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36751044)

  • 61. Ustekinumab Is Associated with Real-World Long-Term Effectiveness and Improved Health-Related Quality of Life in Crohn's Disease.
    Forss A; Clements M; Myrelid P; Strid H; Söderman C; Wagner A; Andersson D; Hjelm F; ; Olén O; Halfvarson J; Ludvigsson JF
    Dig Dis Sci; 2023 Jan; 68(1):65-76. PubMed ID: 35459973
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prospective observational study on Stelara (ustekinumab) assessing effectiveness in Crohn's disease (PROSE): a 16-week follow-up.
    Forss A; Clements M; Myrelid P; Strid H; Söderman C; Wagner A; Andersson D; Hjelm F; ; Olén O; Ludvigsson JF; Halfvarson J
    Scand J Gastroenterol; 2021 Jun; 56(6):680-686. PubMed ID: 33794731
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Persistence, Dose Titration, and Health Care Resource Utilization Among Crohn's Disease Patients Treated With Ustekinumab: A Real-World Analysis in the United States.
    Obando C; Ding Z; Muser E; Vaidya N; Qiang W; Sun X; Wang H; Mallampati R; Xie L
    Adv Ther; 2020 May; 37(5):2127-2143. PubMed ID: 32193810
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.
    D'Haens G; Panaccione R; Baert F; Bossuyt P; Colombel JF; Danese S; Dubinsky M; Feagan BG; Hisamatsu T; Lim A; Lindsay JO; Loftus EV; Panés J; Peyrin-Biroulet L; Ran Z; Rubin DT; Sandborn WJ; Schreiber S; Neimark E; Song A; Kligys K; Pang Y; Pivorunas V; Berg S; Duan WR; Huang B; Kalabic J; Liao X; Robinson A; Wallace K; Ferrante M
    Lancet; 2022 May; 399(10340):2015-2030. PubMed ID: 35644154
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Dual-Targeted Therapy with Upadacitinib and Ustekinumab in Medically Complex Crohn's Disease.
    Miyatani Y; Choi D; Choi NK; Rubin DT
    Dig Dis Sci; 2024 Feb; 69(2):355-359. PubMed ID: 38112840
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Predictive models assessing the response to ustekinumab highlight the value of therapeutic drug monitoring in Crohn's disease.
    Liefferinckx C; Hubert A; Thomas D; Bottieau J; Minsart C; Cremer A; Amininejad L; Vallée F; Toubeau JF; Franchimont D
    Dig Liver Dis; 2023 Mar; 55(3):366-372. PubMed ID: 35977875
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Ustekinuma b for Crohn's Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study.
    Straatmijer T; Biemans VBC; Hoentjen F; de Boer NKH; Bodelier AGL; Dijkstra G; van Dop WA; Haans JJL; Jansen JM; Maljaars PWJ; van der Marel S; Oldenburg B; Ponsioen CY; Visschedijk MC; de Vries AC; West RL; van der Woude CJ; Pierik M; Duijvestein M; van der Meulen-de Jong AE
    J Crohns Colitis; 2021 Nov; 15(11):1920-1930. PubMed ID: 33909062
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Ustekinumab serum concentrations are associated with clinical outcomes in Crohn's disease - a regional multi-center pilot study.
    Thomann AK; Schulte LA; Globig AM; Hoffmann P; Klag T; Itzel T; Teufel A; Schreiner R; Scheffe N; Ebert MP; Wehkamp J; Gauss A; Hasselblatt P; Klaus J; Reindl W
    Z Gastroenterol; 2020 May; 58(5):439-444. PubMed ID: 32045954
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
    Sands BE; Irving PM; Hoops T; Izanec JL; Gao LL; Gasink C; Greenspan A; Allez M; Danese S; Hanauer SB; Jairath V; Kuehbacher T; Lewis JD; Loftus EV; Mihaly E; Panaccione R; Scherl E; Shchukina OB; Sandborn WJ;
    Lancet; 2022 Jun; 399(10342):2200-2211. PubMed ID: 35691323
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
    Ferrante M; Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens GR; van der Woude CJ; Danese S; Diamond RH; Oortwijn AF; Tang KL; Miller M; Cornillie F; Rutgeerts PJ;
    Gastroenterology; 2013 Nov; 145(5):978-986.e5. PubMed ID: 23954314
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effectiveness of ustekinumab in patients with refractory Crohn's disease: a multicentre real-life study in Italy.
    Scribano ML; Aratari A; Neri B; Bezzio C; Balestrieri P; Baccolini V; Falasco G; Camastra C; Pantanella P; Monterubbianesi R; Tullio A; Saibeni S; Papi C; Biancone L; Cosintino R; Faggiani R
    Therap Adv Gastroenterol; 2022; 15():17562848211072412. PubMed ID: 35186121
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease.
    Battat R; Kopylov U; Bessissow T; Bitton A; Cohen A; Jain A; Martel M; Seidman E; Afif W
    Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1427-1434.e2. PubMed ID: 28365485
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Safety and Potential Efficacy of Escalating Dose of Ustekinumab in Pediatric Crohn Disease (the Speed-up Study): A Multicenter Study from the Pediatric IBD Porto Group of ESPGHAN.
    Yerushalmy-Feler A; Pujol-Muncunill G; Martin-de-Carpi J; Kolho KL; Levine A; Olbjørn C; Granot M; Bramuzzo M; Rolandsdotter H; Mouratidou N; Hradsky O; Scarallo L; Matar M; Rimon RM; Rinawi F; Shalem T; Najajra H; de Meij T; Aloi M; Rodríguez-Belvís MV; Alvisi P; Schneider AM; van Rheenen P; Navas-López VM; Kiparissi F; Barrio J; Turner D; Cohen S
    J Pediatr Gastroenterol Nutr; 2022 Dec; 75(6):717-723. PubMed ID: 36084231
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy.
    Bermejo F; Jiménez L; Algaba A; Vela M; Bastida G; Merino O; López-García A; Melcarne L; Rodríguez-Lago I; de la Maza S; Bouhmidi A; Barreiro-de Acosta M; López-Serrano P; Carrillo-Palau M; Mesonero F; Orts B; Bonillo D; Granja A; Guerra I
    Inflamm Bowel Dis; 2022 Jan; 28(1):41-47. PubMed ID: 33528018
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effectiveness and safety of ustekinumab in bio-naïve Crohn's disease patients: a multicentre observational retrospective study.
    Teresa VD; Rául OM; Marisa I; Claudia HG; Esteban FV; Luigi M; Mª Mar MR; Lilyan KC; Luisa CP; Ángel PD; Raquel VL; Noemí MM; Benito VJ; Marta LS; Beatriz LC; Francisco MG; Pau GÁ; Federico AA
    Therap Adv Gastroenterol; 2023; 16():17562848231153560. PubMed ID: 36777363
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.
    Rutgeerts P; Gasink C; Chan D; Lang Y; Pollack P; Colombel JF; Wolf DC; Jacobstein D; Johanns J; Szapary P; Adedokun OJ; Feagan BG; Sandborn WJ
    Gastroenterology; 2018 Oct; 155(4):1045-1058. PubMed ID: 29909019
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Ustekinumab in Crohn's disease: real-world outcomes and predictors of response.
    Lorenzo González L; Valdés Delgado T; Vázquez Morón JM; Castro Laria L; Leo Carnerero E; Maldonado Pérez MB; Sánchez Capilla D; Pallarés Manrique H; Sáez Díaz A; Argüelles Arias F;
    Rev Esp Enferm Dig; 2022 May; 114(5):272-279. PubMed ID: 33393332
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Ustekinumab is effective in biological refractory Crohn's disease patients-regardless of approval study selection criteria.
    Saman S; Goetz M; Wendler J; Malek NP; Wehkamp J; Klag T
    Intest Res; 2019 Jul; 17(3):340-348. PubMed ID: 31129948
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn's Disease Likely to Achieve Endoscopic and Biochemical Remission.
    Hanžel J; Zdovc J; Kurent T; Sever N; Javornik K; Tuta K; Koželj M; Smrekar N; Novak G; Štabuc B; Dreesen E; Thomas D; Vovk T; Grabnar I; Drobne D
    Clin Gastroenterol Hepatol; 2021 Jan; 19(1):111-118.e10. PubMed ID: 32109630
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Efficacy of Adalimumab in Korean Patients with Crohn's Disease.
    Sohn IW; Kim ST; Kim B; Lee HJ; Park SJ; Hong SP; Kim TI; Kim WH; Cheon JH
    Gut Liver; 2016 Mar; 10(2):255-61. PubMed ID: 26470766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.